1. Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013; 381:63–72.
Article
2. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009; 61:1454–61.
Article
3. Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol. 2002; 29:1694–7.
4. Okumura T, Tanno S, Ohhira M, Nozu T. The rate of polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a clinic where primary care physicians are working in Japan. Rheumatol Int. 2012; 32:1695–9.
Article
5. Kim HA, Lee J, Ha YJ, Kim SH, Lee CH, Choi HJ, et al. Induction of remission is difficult due to frequent relapse during tapering steroids in Korean patients with polymyalgia rheumatica. J Korean Med Sci. 2012; 27:22–6.
Article
6. Lee JH, Choi ST, Kim JS, Yoon BY, Kwok SK, Kim HS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013; 33:1475–80.
Article
7. Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012; 71:484–92.
Article
8. Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum. 2007; 57:803–9.
Article
9. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002; 347:261–71.
Article
10. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis. 1981; 40:1–5.
Article
11. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum. 1984; 13:322–8.
Article
12. González-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003; 33:38–48.
Article
13. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Mattey DL, Amoli MM, et al. IL-6 promoter polymorphism at position-174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol. 2002; 20:179–84.
14. Gonzalez-Gay MA, Garcia-Porrua C, Ollier WE. Polymyalgia rheumatica and biopsy-proven giant cell arteritis exhibit different HLA-DRB1* associations. J Rheumatol. 2003; 30:2729.
15. Cid MC, Ercilla G, Vilaseca J, Sanmarti R, Villalta J, Ingelmo M, et al. Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen. Arthritis Rheum. 1988; 31:678–82.
Article
16. Pipitone N, Salvarani C. Update on polymyalgia rheumatica. Eur J Intern Med. 2013; 24:583–9.
Article
17. Frearson R, Cassidy T, Newton J. Polymyalgia rheumatica and temporal arteritis: evidence and guidelines for diagnosis and management in older people. Age Ageing. 2003; 32:370–4.
Article
18. Franzén P, Sutinen S, von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol. 1992; 19:273–6.
19. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008; 372:234–45.
Article
20. Salvarani C, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fif-ty-year period. Arthritis Rheum. 2004; 51:264–8.
Article
21. Chang HK, Hur SH, Chung HR. A Case of Giant Cell Arteritis developed in Polymyalgia Rheumatica. J Korean Rheum Assoc. 2000; 7:72–6.
22. Seo JW, Hur J, Kim HO, Jeon DH, Baek JH, Kim JH, et al. A case of atypical giant cell arteritis presenting as raynaud's phenomenon and diagnosed by random temporal artery biopsy. J Korean Rheum Assoc. 2010; 17:278–82.
Article
23. Kang MI, Park HJ, Jeon HM, Kang Y, Lee SW, Lee SK, et al. A case of atypical giant cell arteritis presenting as a fever of unknown origin. J Rheum Dis. 2012; 19:299–301.
Article
24. Herná ndez-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med. 2009; 169:1839–50.
25. Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010; 49:186–90.
Article
26. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997; 40:1873–8.
Article
27. Barraclough K, Liddell WG, du Toit J, Foy C, Dasgupta B, Thomas M, et al. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Fam Pract. 2008; 25:328–33.
Article
28. Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G, et al. Acutephase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 2005; 53:33–8.
Article
29. Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005; 32:65–73.
30. Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis. 2003; 62:1189–94.
Article
31. Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum. 2007; 57:810–5.
Article
32. Binard A, de Bandt M, Berthelot JM, Saraux A. Inflammatory Joint Disease Working Group of the French Society for Rheumatology. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum. 2008; 59:263–9.
Article
33. Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al. Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004; 141:493–500.